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Herpes simplex virus enhances chemokine
function through modulation of receptor trafﬁcking
and oligomerization
Nadia Martinez-Martin1,w, Abel Viejo-Borbolla1,w, Rocı´o Martı´n1, Soledad Blanco1, Jeffrey L. Benovic2,
Marcus Thelen3 & Antonio Alcamı´1,4
Glycoprotein G (gG) from herpes simplex virus 1 and 2 (HSV-1 and HSV-2, important human
neurotropic pathogens) is the ﬁrst viral chemokine-binding protein found to potentiate
chemokine function. Here we show that gG attaches to cell surface glycosaminoglycans and
induces lipid raft clustering, increasing the incorporation of CXCR4 receptors into these
microdomains. gG induces conformational rearrangements in CXCR4 homodimers and
changes their intracellular partners, leading to sustained, functional chemokine/receptor
complexes at the surface. This results in increased chemotaxis dependent on the cholesterol
content of the plasma membrane and receptor association to Src-kinases and phosphatidy-
linositol-3-kinase signalling pathways, but independent of clathrin-mediated endocytosis.
Furthermore, using electron microscopy, we show that such enhanced functionality is asso-
ciated with the accumulation of low-order CXCR4 nanoclusters. Our results provide insights
into basic mechanisms of chemokine receptor function and into a viral strategy of immune
modulation.
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T
he highly prevalent pathogens Herpes simplex virus type 1
and 2 (HSV-1 and HSV-2, respectively) establish latency
in the peripheral nervous system and cause a variety of
diseases from cold sores to encephalitis1,2. The different outcomes
of HSV infection depend on the interplay between the virus and
the immune system. One of the strategies of immune modulation
mediated by herpes viruses consists of the expression of viral
chemokine-binding proteins (vCKBP), secreted proteins that bind
chemokines with high afﬁnity3. All vCKBPs described to date
inhibit the biological function of chemokines4. The sole exception
is glycoprotein G (gG) from HSV-1 and HSV-2 (gG1 and gG2,
respectively), which increases chemokine-mediated cell migration
and signalling5. The lack of gG expression in HSV-1 leads to virus
attenuation in mouse models of infection6–8 but there are
no reports addressing the role of gG in HSV-2 infections.
Modulation of chemokine activities by gG may contribute to
HSV-1 and HSV-2 pathogenesis.
Chemokines are chemotactic cytokines that modulate cell
activation and orchestrate leukocyte recruitment to the sites of
injury or infection. Alterations in the chemokine network are in
the onset and development of cancer, autoimmunity and
neuroinﬂammatory diseases9,10. Chemokines are presented by
glycosaminoglycans (GAGs) to speciﬁc G-protein-coupled
receptors (GPCRs), triggering a variety of biological responses.
Among the chemokines modulated by HSV gG is CXCL12, which
binds to the ubiquitous CXCR4 receptor. The CXCL12/CXCR4
axis regulates HIV infection, plays relevant roles in the immune
and nervous systems and is involved in multiple pathological
conditions11.
Chemokine receptor internalization is tightly controlled since
it regulates the amount of available receptor and thereby
chemokine-triggered responses12. Although clathrin-dependent
mechanisms govern the internalization of most chemokine
receptors, lipid rafts are also involved in GPCR trafﬁcking as
well as in the internalization of other types of receptors, integrins
and viruses13. Lipid rafts are highly dynamic entities that
aggregate forming larger structures, such as those located at the
leading edge of migrating cells. These specialized platforms allow
an optimal spatial interaction between ligands, receptors and
signalling partners, and thus are believed to be pivotal for
processes such as migration, lymphocyte activation and viral
infection14,15.
Our previous work identiﬁed HSV gG as the ﬁrst vCKBP that
enhances the function of chemokines in vitro and in vivo through
an unknown mechanism5. Here, we show that secreted gG (SgG)
from HSV binds to GAGs at the cell surface triggering the
stabilization of functional chemokine/receptor complexes in
speciﬁc microdomains of the plasma membrane, leading to a
cholesterol-dependent increase of chemotaxis and signalling.
Furthermore, we ﬁnd a direct association between the enhanced
responsiveness to chemokines and an increased nanoclustering of
CXCR4 at the surface of SgG-stimulated cells.
These ﬁndings strengthen our understanding of a novel
immunomodulatory strategy exerted by human herpes viruses,
and provide relevant insights into the biology of chemokines and
their receptors.
Results
HSV SgG binds to cell surface GAGs. We have previously shown
that recombinant secreted HSV-1 and HSV-2 gG (SgG1 and
SgG2, respectively) interact with chemokines through their GAG-
binding domain without inhibiting chemokine binding to the
GPCR5. We hypothesized that SgG could interact with the plasma
membrane to modulate chemokine interaction with the GPCR.
Viral protein binding to plasma membrane was detected by
immunoﬂuorescence and ﬂow cytometry assays using human
primary monocytes and CHO cells (Fig. 1a,b,e,f, respectively).
Upon CXCL12 stimulation at 37 C, both SgG2 and CXCR4
showed signiﬁcant co-localization at one of the cell edges (Fig. 1a,
bottom row, and Supplementary Fig. 1a), whereas no changes in
receptor redistribution were evident at 4 C (Fig. 1b).
We checked whether HSV gG interacted with the cell surface
through GAGs, as shown for other vCKBPs16,17. SgG2 interacted
with heparin with high afﬁnity, as demonstrated by surface
plasmon resonance (SPR, Fig. 1c) and heparin–sepharose bead
pull-down assays (Supplementary Fig. 1b). SgG2–heparin binding
was competitively inhibited by heparan sulfate and chondroitin
sulfate A and B, indicating that SgG2 interacts with different
GAGs with variable afﬁnities (Fig. 1d). Moreover, SgG bound to
wild-type CHO-K1 cells, but not to mutant CHO-618 cells
deﬁcient in GAG expression18 conﬁrming the relevance of GAGs
in the interaction of SgG with the cell surface, as determined by
ﬂow cytometry (Fig. 1e) and immunoﬂuorescence (Fig. 1f). As a
control for positive or no binding to GAGs, we used vaccinia
virus B18 and ectromelia virus sema proteins, respectively19
(Fig. 1e,f). We also tested virus-free supernatants from HSV-2-
infected cultures, containing secreted gG2. HSV-1 gG is not
secreted during infection20. gG2 present in supernatants of
HSV-2-infected cells bound CHO-K1. However, protein binding
dropped with CHO-618 cells (Supplementary Fig. 1c). SgG1 also
bound to the cell surface through GAGs as determined by ﬂow
cytometry and immunoﬂuorescence (Fig. 1e,f).
SgG2 modiﬁes CXCR4 trafﬁcking and prevents internalization.
CXCR4 internalization is not required for signalling, but it serves
as a regulatory mechanism to control the strength and duration of
cellular responses to CXCL12 (ref. 12). We investigated the effect
of SgG2 on CXCR4 trafﬁcking. SgG2 reduced CXCL12-promoted
internalization of CXCR4 in MM-1 and HEK-293T cells, leading
to a signiﬁcant increase of CXCR4 at the surface (Fig. 2a,d,
respectively). The effect was more pronounced when the cells
were pre-incubated with SgG2 before stimulation with CXCL12
(Fig. 2a, SgG2F–CXCL12 condition) in comparison with cells
stimulated with the SgG2:CXCL12 complex, suggesting that SgG2
modiﬁed cell membrane receptor trafﬁcking independently of the
presence of the chemokine. SgG1 was also capable of blocking
chemokine-induced internalization of CXCR4 in Jurkat T cells
(Fig. 2b).
A delay in chemokine-triggered internalization and a sig-
niﬁcant increase in surface receptor levels were also observed in
human primary monocytes in the presence of SgG2, but not of
pseudorabies virus (PRV)–SgG, a vCKBP that inhibits chemokine
function21 (Fig. 2c).
Next, we analysed CXCR4 trafﬁcking in live cells by time-lapse
video microscopy using HEK-293T cells stably expressing CXCR4
engineered with a tag derived from the acyl carrier protein
(ACP)22. The receptor constitutively trafﬁcked in the mock-
stimulated cells, whereas some areas of CXCR4 accumulation
were observed at the cell surface upon SgG2 treatment (Fig. 2d).
Incubation with CXCL12 reduced the amount of CXCR4 at the
surface over time. In contrast, stimulation with the CXCL12:SgG2
complex led to a sustained presence of the receptor at the surface
(Fig. 2d). Internalizing vesicles containing CXCR4 and CXCL12
were readily observed upon treatment with the chemokine alone
(Supplementary Movie 1), whereas they were much scarcer in
cells stimulated with the SgG2:CXCL12 complex, where spots
of chemokine and receptor were stabilized at the surface
(Supplementary Movie 2).
A quantitative analysis showed a signiﬁcant increase of
CXCL12 in the proximity of CXCR4 when the chemokine was
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bound to SgG2 (Supplementary Fig. 2a). After an acidic wash,
which removes surface-bound but not internalized CXCL12, less
intracellular CXCL12 was observed in the SgG2:CXCL12-treated
cells, in agreement with a sustained presence of CXCR4/CXCL12
at the cell surface upon SgG2 exposure (Supplementary Fig. 2b).
We next addressed whether the effect of SgG2 on trafﬁcking
was CXCR4 speciﬁc by analysing the trafﬁcking of two
chemokine receptors, CXCR5 and CCR2. SgG2 signiﬁcantly
increased CXCR5 levels at the cell surface when compared with
the CXCL13 control (Fig. 2e). SgG2 also enhances CXCL13-
mediated chemotaxis5. Interestingly, although SgG2 neither binds
nor potentiates the chemotactic properties of CCL2 (ref. 5),
we also observed a signiﬁcant increase in CCR2 levels at the cell
surface on stimulation with the viral protein, in comparison with
CCL2-treated cells (Fig. 2f). This latter result indicates that both
modiﬁcation of receptor trafﬁcking and chemokine binding are
required to enhance chemokine activity. However, contrary to
what was observed for these GPCRs, SgG2 did not signiﬁcantly
modify the internalization of CD71 or transferrin receptor
(Fig. 2g).
SgG2 promotes the incorporation of CXCR4 into lipid rafts.
We next asked whether SgG2 could modulate the plasma mem-
brane localization of CXCR4 using Jurkat cells transduced with
the ﬂuorescent lipid raft marker Lck10mCherry23,24. Neither
mock-treated nor CXCL12-stimulated cells showed high co-
localization values between endogenous CXCR4 and lipid rafts
(Fig. 3a). On the other hand, SgG2 alone or the complex
SgG2:CXCL12 signiﬁcantly increased the presence of CXCR4 in
Lck10mCherry-enriched domains, whereas PRV–SgG did not
(Fig. 3a). Focal clusters of Lck10mCherry were observed only
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Figure 1 | SgGs interact with GAGs at the cell surface. (a,b) SgG2 binding to the surface of human primary monocytes. Freshly isolated monocytes were
incubated with SgG2 alone or in the presence of CXCL12 at 37 C (a) or 4 C (b). SgG2 and endogenous CXCR4 were detected using speciﬁc polyclonal
antibodies. BF, bright ﬁeld images. Scale bar, 2 mm. (c) Sensorgram depicting the interaction between SgG2 and heparin by SPR. SgG2 was injected at
different concentrations over biotinylated-heparin immobilized on a chip. The arrow indicates the end of the injection. All curves were analysed with the
BIAevaluation software and kinetic parameters for the SgG2–heparin binding are shown in the inset table. (d) SgG2 interacts with other sulfated GAGs.
SgG2, alone or in combination with increasing concentrations of the soluble heparin, heparan sulfate (HS) and chondroitin sulfate A (CS A) or B (CS B), was
injected over the BIAcore chip coated with heparin. The percentage of SgG2 bound respective to protein binding in the absence of soluble GAG was plotted
as a function of the concentration of each competitor GAG. (e) Binding of SgG2 (100 and 500ng, light and dark red histograms, respectively) and SgG1
(400 and 600ng, orange and brown histograms, respectively) to CHO cells. The viral proteins were incubated with wild-type CHO-K1 cells (upper row) or
GAG-deﬁcient CHO-618 cells (lower row) during 30min at 4 C and surface-bound proteins were detected by ﬂow cytometry. Vaccinia virus (VACV) B18
and ectromelia virus (ECTV) sema were used as positive and negative controls, respectively (left histograms). (f) Immunoﬂuorescence experiment
showing binding of SgG1, SgG2 or the control proteins VACV B18 and ECTV sema to the surface of CHO cells. Proteins were stained with an anti-SgG1
monoclonal antibody, an anti-gG2 polyclonal antibody or anti-His antibodies, and DNA was stained with DAPI. Scale bar, 10mm. All assays shown are
representative of at least two independent experiments.
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upon SgG2 stimulation in regions where no membrane rufﬂing
was apparent (Supplementary Fig. 3a). The SgG2-induced
clustering of lipid rafts and the enrichment of CXCR4 in these
domains were dependent on the cholesterol content of the plasma
membrane, since both effects were abrogated when cells were
pretreated with the cholesterol-depleting agent methyl-beta-
cyclodextrin (MbCD) (Fig. 3a and Supplementary Fig. 3a, lower
rows). Further evidence of the SgG2-promoted effect on lipid
rafts and CXCR4 redistribution to these microdomains was
obtained from western blot analysis of cell membrane fractions
isolated according to their lipid raft content (Fig. 3b). SgG2
enhanced CXCR4 incorporation into lipid raft-enriched
membrane fractions, in comparison with both mock- or
CXCL12-stimulated Jurkat cells. LCK mostly localized to lipid
raft membrane fractions after activation with CXCL12.
Interestingly, an increase in the lipid raft-associated protein
CXCL12
SgG2:
CXCL12
CXCL12 CXCR4 Merge Composite
CXCL12 CXCR4 Merge Composite
Mock
SgG2
CXCR4 Composite
CXCR4 Composite
t=30 min
t=50 min
Mock
SgG2
CXCL12
SgG2:
CXCL12
t=30 min
t=50 min
0
50
100
150
200
*
*
0 15 30 60
0
50
100
150
200
0
50
100
150
200 ***
*
**
0
40
80
120 ***
**
***
0
40
80
120 *
***
* * **
200
0
0 5 15 30 45
50
100
150 *
*
Su
rfa
ce
 C
XC
R4
(%
 of
 co
ntr
ol)
CXCL12
SgG2F:CXCL12
SgG2:CXCL12
SgG2
Su
rfa
ce
 C
XC
R4
(%
 of
 co
ntr
ol)
Su
rfa
ce
 C
XC
R4
(%
 of
 co
ntr
ol)
Time (min)
CXCL12
PRV-SgG:CXCL12
PRV-SgG
SgG2:CXCL12
SgG2
SgG1:CXCL12
CXCL12
SgG1
Su
rfa
ce
 C
XC
R5
(%
 of
 co
ntr
ol)
SgG2:CXCL13
SgG2
CXCL13
Su
rfa
ce
 C
CR
2
(%
 of
 co
ntr
ol)
SgG2F–CCL2
SgG2–CCL2
SgG2
CCL2
Su
rfa
ce
 C
D7
1
(%
 of
 co
ntr
ol)
Time (min)
Tfr
SgG2-Tfr
SgG2
Figure 2 | HSV SgGs modify GPCR trafﬁcking and upregulate the level of chemokine receptors at the cell surface. Effect of (a) SgG2 and (b) SgG1 on
CXCR4 surface levels in MM-1 and Jurkat cells, respectively. SgG2F:CXCL12 indicates cells that were incubated with SgG2 for 30min before the addition of
the chemokine. In all the cases, cells were stimulated for 30min with 1.5mM SgG, 15 nM CXCL12 or SgG:CXCL12 at a 100:1 molar ratio, and surface receptor
levels were detected by ﬂow cytometry. (c) Amount of CXCR4 at the surface of primary human monocytes. Primary monocytes were mock treated or
stimulated with 15 nM CXCL12, 750nM SgG2 or PRV–SgG, or SgG2:CXCL12 and PRV–SgG:CXCL12 at a 50:1 molar ratio for different time points and CXCR4
surface levels were detected by ﬂow cytometry. Plot shows two independent assays performed in triplicates. (d) Analysis of CXCL12 and CXCR4
localization by time-lapse video microscopy of ACP-CXCR4 expressing HEK-293T cells that were mock treated or stimulated with 800nM SgG2,
8 nM CXCL12 or the complex SgG2:CXCL12 at a 100:1 molar ratio. Selected frames corresponding to the time when the movie started (t¼ 30min) and
20min later (t¼ 50min) are shown. Scale bar, 10mm. (e) Expression of CXCR5 at the cell surface of m300-19 B cells. Leukocytes were stimulated with
15 nM chemokine, 1.5 mM SgG2 or the complex SgG2:chemokine at a 100:1 molar ratio for 15min. (f) Expression of CCR2 at the surface of MM-1 cells. Cells
were stimulated with 5 nM CCL2, 500nM SgG2 or a combination of CCL2 and SgG2 at a 1:100 ratio for 15min. SgG2F:CCL2 indicates cells that were
incubated with SgG2 for 30min before the addition of the chemokine. (g) Surface expression of CD71 measured by ﬂow cytometry in MM-1 cells on
stimulation with 1mgml 1 transferrin (Tfr), 1.5mM SgG2 or both. In all the cases, plots show one assay run in triplicates representative of at least
three independent assays unless indicated. The expression of the receptors at the surface was represented as the percentage of the value obtained for
mock-treated cells at each time point. Data show mean±s.d. One-tailed unpaired t-test, *Po0.05, **Po0.01, ***Po0.001.
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LCK as well as the ganglioside GM1 in the fractions
corresponding to lipid raft-rich membranes was also apparent
upon SgG2 stimulation of the cells. This demonstrated that GM1
and LCK maintain a lipid raft localization after exposure to SgG2.
These effects correlated with the SgG2-mediated increase in lipid
raft clustering and GM1 surface staining observed in our
microscopy studies (Supplementary Fig. 3a and Supplementary
Fig. 4a). In addition, SgG2 increased CXCL12 co-localization with
the ﬂuorescent Lck10mCherry lipid raft marker in cells, suggesting
that the complex SgG2:CXCL12 preferentially binds to lipid
raft-associated CXCR4 (Supplementary Fig. 2c).
Upon CXCL12 stimulation, the cell polarizes and GM3-
enriched gangliosides are found at the leading edge, whereas
GM1 gangliosides and adhesion molecules localize at the
uropod15. CXCL12 stimulation of primary monocytes drove the
accumulation of CXCR4 into GM3 rafts, as described25 (Fig. 4a).
Interestingly, SgG2 (Fig. 4a) and, to a lesser extent, SgG1
(Supplementary Fig. 3b,c) signiﬁcantly increased the
incorporation of CXCR4 into GM3 rafts in comparison with
mock-treated cells. Contrary to SgG1 and SgG2, PRV–SgG
blocked chemokine-promoted relocalization of CXCR4 to
GM3-enriched areas in favour of a higher incorporation into
GM1 rafts (Fig. 4b). In addition, although both GM1 and GM3
were upregulated in the presence of SgG2 (Supplementary
Fig. 4a,b), CXCR4 was speciﬁcally redirected to clusters of
GM3-enriched rafts (Fig. 4 and Supplementary Fig. 4c,d).
SgG2 modiﬁes CXCR4 interaction with intracellular molecules.
Following CXCL12 stimulation, CXCR4 is phosphorylated at its
cytosolic C-tail by GPCR-kinases (GRKs). This event determines
the recruitment of b-arrestins to the cytoplasmic domain
blocking further G-protein activation, desensitizing CXCR4 and
regulating various trafﬁcking events12,26.
* * ** *
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Figure 3 | SgG2 promotes clustering of lipid rafts and incorporation of CXCR4 to these microdomains. (a) Quantitative analysis of lipid rafts and CXCR4
co-localization. Jurkat Tcells were transduced with the ﬂuorescent lipid raft marker Lck10mCherry (in red), incubated with CXCL12 alone or in combination
with SgG2 or PRV–SgG, and stained for endogenous CXCR4 (shown in green). Representative images from two independent assays are shown. The
intensity correlation analysis (ICA) method was utilized to quantify co-localization of the ﬂuorescent signals. As a result, two coefﬁcients were calculated:
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ﬁeld. Scale bar, 2 mm. Data show mean±s.d. Two-tailed unpaired t-test, *Po0.05, **Po0.01 (b) Analysis of CXCR4 distribution in lipid raft-enriched
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(15 nM and 1.5mM, respectively) for 15min and then cell membranes were lysed in Triton X-100 and ultracentrifuged in a sucrose gradient. CXCR4 was
analysed in the different membrane fractions along with the lipid raft marker GM1, detected by dot blot using HRP-conjugated cholera toxin. The protein
LCK was also analysed as an additional marker for lipid raft-enriched membranes. Full blots are shown in Supplementary Fig. 5c. The experiment was
performed twice with similar results. Molecular masses are indicated in kDa.
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We analysed the phosphorylation status of the receptor in the
presence of SgG2 using a phospho-speciﬁc antibody directed
against phospho-serine 330 (pSer330), (ref. 26). SgG2 reduced the
phosphorylation level of the steady-state receptor and inhibited
chemokine-mediated phosphorylation (Fig. 5a).
We next analysed the distribution of b-arrestin-2 and CXCR4
in Jurkat cells. SgG2 reduced the intracellular accumulation
of the receptor into b-arrestin-2-positive vesicles (Fig. 5b). The
diminished interaction with b-arrestin-2 correlated with a
reduced co-localization between CXCL12-activated CXCR4 and
a-adaptin, suggesting an impaired interaction of the receptor
with the clathrin-dependent endocytic machinery (Fig. 5c).
This observation was consistent with the increased presence of
CXCR4 at the surface of SgG2-stimulated cells. Furthermore, by
performing bioluminescence resonance energy transfer (BRET)
assays using GFP- and luciferase-tagged CXCR4, we observed
that SgG2 triggered speciﬁc time-dependent conformational
rearrangements within CXCR4 homodimers, different to those
induced by CXCL12 alone (Fig. 5d).
SgG2 function depends on lipid raft integrity. We next mea-
sured the migration of freshly isolated human monocytes and
MM-1 cells in the presence of chemical inhibitors of clathrin-
coated pits (CCP) formation (chlorpromazine) or lipid raft dis-
rupting or sequestering reagents (ﬁlipin, nystatin and MbCD).
SgG2 displaced the chemotactic curve towards lower concentra-
tions of the chemokine, whereas PRV:SgG inhibited chemotaxis
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Figure 4 | HSV–SgG increases the localization of CXCR4 in GM3 rafts in primary human monocytes. Analysis of endogenous CXCR4 co-localization
with GM3 and GM1 lipid rafts in freshly isolated monocytes. Cells were stimulated for 5min at 37 C as indicated, and then ﬁxed and stained for
(a) CXCR4 and GM3 rafts using speciﬁc antibodies or for (b) CXCR4 and GM1 lipid rafts using speciﬁc antibodies and FITC-conjugated cholera toxin B.
Representative images are shown. Scale bar, 2 mm. Plots below the panels show the PC and ICQ values (mean±s.d.) obtained for the quantiﬁcation of co-
localization between CXCR4-GM3 and CXCR4-GM1 in 10 and 25 monocytes, respectively. The assay shown is representative of two independent assays.
Two-tailed unpaired t-test was performed *Po0.05, **Po0.01, ***Po0.001.
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(Fig. 6a), as previously shown5. Perturbation of lipid raft
formation by ﬁlipin slightly affected migration towards
CXCL12, but it completely abrogated SgG2-mediated
enhancement (Fig. 6b). On the contrary, the inhibition of CCP
formation did not signiﬁcantly abolish SgG2-mediated
potentiation of monocyte chemotaxis (Fig. 6c). The doses of
chlorpromazine used in the migration assays were proven to be
functional, as indicated by the blockade of the transferrin-induced
CD71 endocytosis (Supplementary Fig. 5e). In addition,
disruption of lipid raft integrity by distinct compounds
(nystatin and MbCD) inhibited SgG2-induced increase in
CXCL12-mediated migration (Fig. 6d,e). To further determine
the signalling pathways involved in chemotaxis potentiation,
we utilized Ly294002, a compound blocking phosphoinositide
3-kinase (PI3K) function and PP2, an inhibitor of Src-kinases.
Both abrogated SgG2-induced increase of chemotaxis (Fig. 6f,g).
gG2 increases CXCR4 nanoclusters at the cell surface. To assess
whether SgG2-mediated increase in cell responsiveness to the
chemokine was related to changes in the oligomerization state of
CXCR4, as well as to address the effect on the receptor by means
of a higher resolution technique, we prepared surface replicas by
label-fracture of Jurkat T cells27,28, which were analysed by
electron microscopy (Fig. 7). We observed a signiﬁcant increase
in the amount of small clusters of CXCR4 (oligomers formed by
r6 gold particles) at the surface of T cells stimulated with SgG2,
in comparison with mock- and CXC12-treated cells (Fig. 7). The
percentage of clusters containing 2, 3 and 4–9 gold particles,
respective to the total number of particles in each case, was also
increased in SgG2 and SgG2:CXCL12-stimulated cells (Fig. 7e, left
inset). In parallel, a reduction in the percentage of CXCR4
monomers in cells treated with SgG2 was observed compared
with the mock-treated cells (Fig. 7e, left inset). Moreover,
consistent with our previous results, we observed a signiﬁcant
enhancement in the total number of gold particles in SgG2-
treated cells (Fig. 7e, right inset). Representative whole-cell replica
images corresponding to CXCL12- and SgG2:CXCL12-stimulated
cells are shown in Supplementary Figs 6 and 7. Similar results
were obtained for HEK-293T cells stably expressing CXCR4
(Supplementary Fig. 8).
Discussion
Dysregulation of the chemokine network affects the onset of viral
infections and the development of immunopathologies. Here, we
have addressed the molecular basis regulating the ﬁrst example of
chemokine potentiation by a viral protein5. Our results show that
HSV–SgG interaction with the cell leads to the enrichment of
oligomeric chemokine receptor complexes and their sustainment
at the cell surface. Although a correlation between an augmented
presence of CXCR4 at the surface and an improved chemotactic
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response has been previously reported29,30, our studies constitute
the ﬁrst description of a pathogen-encoded protein that modiﬁes
GPCR trafﬁcking and plasma membrane architecture as a novel
immunomodulatory strategy.
SgG2 interacts with GAGs and induces lipid raft clustering,
promoting the incorporation of CXCR4 into these speciﬁc
microdomains and altering receptor trafﬁcking. GPCRs have
seven transmembrane domains and therefore are highly depen-
dent on structural and functional regulation by lipids. In fact,
cholesterol modulates GPCR function either by direct interaction
with the receptor and/or by altering the plasma membrane
environment where the receptor is embedded, a regulation that
seems to be receptor speciﬁc31,32. Thus, the fate of different types
of receptors following SgG2 stimulation could depend on the
afﬁnity and degree of dependency of each receptor for cholesterol.
In accordance with this hypothesis, SgG2 did not signiﬁcantly
modify the internalization of CD71, a receptor with a very low
tendency to interact with cholesterol and that is commonly found
outside lipid rafts33, whereas it modiﬁed the trafﬁcking of all
GPCRs assayed (CXCR4, CXCR5 and CCR2). Interestingly,
contrary to what we observed for CXCR4 and CXCR5, whose
cognate chemokines interact with SgG, SgG2 did not potentiate
CCL2-mediated migration5, in spite of the increase on surface
CCR2 upon SgG2 stimulation. These observations indicate that,
besides the stabilization of the chemokine receptor at the surface,
the chemokine needs to be presented to its receptor as a complex
with the viral protein, further supporting our hypothesis that
SgG2 mimics the role of GAGs presenting chemokines to their
receptors5 (Fig. 8). Alternatively, chemokine binding by SgG2
may increase the local chemokine concentration in the proximity
of the chemokine receptor.
Our results support previous studies suggesting that CXCR4
incorporation into lipid rafts improves the signalling properties of
the receptor30,34. Furthermore, SgG induced a speciﬁc association
of CXCR4 with GM3-enriched rafts, a subtype of lipid rafts found
at the leading edge of migrating leukocytes, whereas it decreased
its incorporation into GM1 or uropod-rafts. SgG2-induced
redistribution of CXCR4 may improve receptor coupling to
speciﬁc pathways, making the cell more prone to sense threshold
concentrations of chemokines that would otherwise be
insufﬁcient to trigger functional responses. This effect may
account in part for the faster and more directional movement
observed in primary monocytes5. In contrast, gG from PRV, a
related protein that inhibits chemokine activity21, prevents the
relocalization of CXCR4 to GM3-containing rafts.
Alterations in receptor distribution at the membrane may
modulate its initial interaction with signalling molecules12,35.
A higher interaction with cholesterol may regulate different
aspects of CXCR4 function, either by promoting more active
conformations of the receptor or by creating a platform for the
association with a speciﬁc set of signalling proteins30,32,36. We
have shown that SgG2-induced redistribution of receptors drives
a conformational rearrangement in CXCR4 dimers distinct to
that caused by CXCL12. We propose that such rearrangements
are transmitted to the cytosolic domain of the GPCR, leading to a
differential recruitment of signalling molecules. In line with our
hypothesis, it has been previously shown that CXCR4 changes its
G-protein-coupling speciﬁcity when the receptor relocates to the
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T-cell immune synapse, a structure characterized by lipid raft
clustering37. The alterations we have observed in the
phosphorylation pattern of CXCR4 C-tail could explain the
diminished recruitment of b-arrestin and the differential
interaction with the canonical clathrin-dependent endocytic
machinery12,35, which would ultimately account for the overall
alterations in trafﬁcking and the increased functionality of surface
chemokine receptors on exposure to SgG2. Our results provide
additional evidence for the observation that functional association
of CXCR4 with Src- and PI3K-signalling routes in the lipid raft
microenvironment leads to an increased sensitization to
chemokines34,38,39. Furthermore, the observation that CXCR4 is
displaced from CCPs and the increased association of the
complex CXCL12/CXCR4 with lipid raft markers could indicate
that chemokine receptors act as ‘lipid-raft-biased’ receptors in the
presence of the viral protein.
Although the oligomerization of some chemokines has been
proven important for receptor activation40,41, whether chemokine
receptors are active as monomers, dimers or higher order
oligomers remains poorly understood42,43. Growing evidence
suggests that non-stimulated receptors co-exist in an equilibrium
of inactive and active conformations, which shifts towards speciﬁc
receptor conformations depending on the ligand triggering the
response. It is well accepted that CXCR4 is able to oligomerize in
the absence of chemokine44–46. However, to our knowledge, there
are no clear reports showing the correlation between CXCR4
aggregation state and its biological activity. We have clearly
demonstrated that SgG2 enhances the functionality of the
CXCR4/CXCL12 pair using signalling and chemotaxis
experiments as readout for cell activation. Interestingly, we
found that such enhanced activation associated with a signiﬁcant
increase in the amount of receptor nanoclusters and their relative
percentage at the surface of SgG2-stimulated cells. We propose
that the reorganization of the receptor in nanoclusters located at
particular subdomains of the plasma membrane predisposes the
receptor to establish a more efﬁcient interaction with signalling
partners, improving cell responsiveness to suboptimal
concentrations of the chemokine.
Proteoglycans (PGs) are GAG-rich signalling co-receptors that
serve as scaffolds for multiple signalling complexes, playing key
roles during processes such as adhesion, cell activation or protein
polarization at the leading edge of migrating cells47. Ligand
binding induces PG clusterization within lipid rafts, a process that
has been related to a PG-dependent route of endocytosis distinct
to that mediated by clathrin48,49. A reasonable explanation for the
phenomena described in this report is that SgG binds PGs
through their extracellular GAGs, leading to PGs patching into
cholesterol-rich domains, where GPCR inclusion is enhanced. In
that scenario, SgG may mimic the function of GAGs, modifying
the quaternary structure of the chemokine presenting it in an
optimal spatial conformation to SgG2-induced CXCR4 oligomers
and increasing the effective activity of CXCL12. SgG2 could also
increase the concentration of the chemoattractant in the local
environment of the receptor thereby increasing the avidity for
receptor binding.
During HSV-2 infection, SgG could immediately bind to the
surface of the infected cell, or neighbouring cells, modifying the
interaction of GPCRs with chemokines produced in the infected
mucosa and enhancing the biological activity of chemokines.
Although the function of SgG in vivo requires further investiga-
tion, we can hypothesize several scenarios where SgG activity
could promote HSV infection. (i) Cell activation could favour
viral replication; for example, downstream effectors or GPCR
signalling, such as MAPKs, are required for efﬁcient HSV
replication50. (ii) We have shown that SgG enhances the activity
of non-proinﬂammatory chemokines5, and SgG could selectively
modify the population of inﬁltrating leukocytes, which, in turn,
could be infected increasing viral loads and spread, or modulate
the immune response facilitating viral immune evasion. (iii)
Membrane remodelling and receptor trafﬁcking modulation by
SgG could serve as a mechanism to increase the availability of
HSV entry receptors. In addition, the dysregulation of the
chemokine receptor trafﬁcking by HSV, in particular that of
CXCR4, may contribute in part to the enhanced susceptibility to
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Figure 7 | Effect of SgG2 on the nanoclustering of CXCR4 at the cell
surface of Tcells. The number and size of clusters present in the replicas of
individual cells was determined by electron microscopy. Selected small ﬁeld
images ( 10.000) showing the distribution of gold particles in cell surface
replicas of (a) mock-treated cells, and (b) 1.5mM SgG2-, (c) 15 nM CXCL12-
or (d) 100:1 molar ratio SgG2:CXCL12-stimulated cells. Scale bar, 200nm.
(e) Quantiﬁcation of gold particle distribution for each experimental
condition (mean±s.e.m.). Data from eight mock-treated cells (4,380 gold
particles), 17 SgG2-stimulated cells (26,291), 18 CXCL12-stimulated cells
(14,476) and 17 SgG2:CXCL12-stimulated cells (22,683) from two
independent assays are represented. (e, left inset) The plot shows the
percentage of clusters of the indicated sizes respective to the total number
of gold particles found in each experimental condition (mean±s.d.).
(e, right inset) Representation of the average total number of gold particles
per cell (mean±s.d.). One-tailed unpaired t-test, *Po0.05, **Po0.01,
***Po0.001.
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HIV infection reported in co-infected individuals51. (iv) Finally,
the well-documented increased risk of HIV-1 infection and
transmission due to HSV-2 infection52 may be partially due to the
activation and enhancement of T-cell migration by HSV-2 (refs
53,54). Whether HSV-2 gG plays a role in these scenarios requires
further investigation.
Membrane trafﬁcking controls many complex and diverse
biological responses, including those triggered by chemokines.
Since chemokines coordinate functions that go beyond the
immune response, the modulation of chemokine receptor
trafﬁcking suggests a role for gG at other stages of HSV infection,
such as the initial colonization of the nervous system, where
chemokines including CXCL12 have an important regulatory
function. In fact, we have found that SgG2 modiﬁes the trafﬁcking
and signalling of the neutrophic growth factor-receptor TrkA,
leading to an increase in axonal growth55.
This work provides a molecular explanation for HSV gG
modulation of chemokine activity. The insights presented here
shed light into basic concepts of the chemokine network biology,
receptor trafﬁcking and HSV immune modulation. To our
knowledge, HSV gG is the ﬁrst vCKBP encoded by a human
pathogen that regulates cell receptor trafﬁcking and oligomeriza-
tion through the modiﬁcation of lipid raft architecture.
Methods
Cells and plasmids. Jurkat (human, peripheral blood, leukemia, T cell) and
MonoMac-1 (MM-1, human, monocyte-like) cells were grown in RPMI 1640
(Sigma) containing 10% fetal bovine serum (FBS) (R-10 medium). m300-19-
hCXCR5 (stably transfected with hCXCR5) were a gift of Dr Bernhard Moser
(Cardiff University) and were grown in R-10 medium supplemented with
b-mercaptoethanol (5 10 5M), sodium pyruvate (1%) and puromycin
(1.5 mgml 1). HEK-293T, MDCK and Vero cells were grown in Dulbecco’s
Modiﬁed Eagle’s medium (DMEM) containing 10% FBS. CHO-K1 and CHO-618
cells were grown in DMEM-F12 1:1 medium containing 10% FBS. All mammalian
cell lines were cultured at 37 C, 5% CO2 in a humidiﬁed incubator. The
ACP-CXCR4 HEK-293T cells and the Lck10mCherry expressing HEK-293T
and MDCK cell lines were generated by lentiviral transduction, as previously
described56. All the cell lines were acquired from the ATCC unless indicated.
Chemokines. Chemokines were obtained from Peprotech (London). CXCL12a-
biotin, kindly provided by I. Clark Lewis, was conjugated with Quantum Dots
(Qdots)–streptavidin (Invitrogen) at a ratio 4:1 (CXCL12-biotin/QD605, mol per
mol) for 15min at room temperature (RT) immediately before the experiments.
Generation and puriﬁcation of recombinant proteins. Recombinant proteins
were generated using the recombinant baculovirus expression system followed by
protein puriﬁcation by afﬁnity chromatography5, and the puriﬁed proteins were
dialysed against HEPES buffer using a Vivaspin500 device (VivaScience). The
SgG1, SgG2 and PRV–SgG constructs used in this study have been previously
described5,21.
Lentiviral transduction, transfection and electroporation of cell lines.
Supernatants used in transduction experiments were produced transfecting
packaging HEK-293T cells with pALPS-CXCR4 or pALPS-Lck10mCherry, psPAX2
and pMD2-G plasmids, as described56. Jurkat cells were incubated with the
supernatants during 72–96 h in the presence of 4 mgml 1 polybrene (Sigma).
Transfection of mammalian cells was carried out using Fugene HD reagent
(Promega). Jurkat cells (20–30 106) in Opti-MEM medium (Gibco) were mixed
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with SgG2 provides a molecular explanation for the enhancement of chemokine functions.
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with 10–30 mg DNA, electroporated in an EasyjecT apparatus (Eurogentec,
Belgium), and grown overnight in R-10 medium.
Isolation of human monocytes. Monocytes were prepared from buffy coats
obtained from the local donor bank (‘Servizio Trasfusion, Svizzera Italiana’,
Lugano, Switzerland) with oral consent from the donors according to Swiss
regulations. The use of buffy coats was approved by the institutional review board
‘Comitato Etico Cantonale, Bellinzona, Switzerland’. Monocytes were isolated
using the Monocyte Isolation kit II (MACS Miltenyi Biotec), following manu-
facturer’s instructions. In brief, peripheral blood mononuclear cells were isolated
from heparinized blood by Ficoll (Lymphoprep) gradient centrifugation and
incubated with FcR blocking reagent. Highly enriched unlabelled monocytes were
obtained by negative selection.
Analysis of protein binding to cells. Cells were incubated on ice for 30min with
puriﬁed proteins or virus-free supernatants from HSV-2-infected cells. Protein
binding was assessed by ﬂow cytometry using an in-house generated rabbit
polyclonal antibody against SgG1, an anti-gG2 antibody (20 mgml 1) (Austral
Biologicals) or an anti-His tag antibody (10 mgml 1) (QIAGEN) to detect vaccinia
virus B18 and ectromelia virus semaphorin (sema) proteins, followed by Alexa
Fluor 488 donkey anti-mouse IgG secondary antibody (Invitrogen) used at
4 mgml 1. The anti-SgG1 antibody was generated by injecting puriﬁed recombi-
nant SgG1 into one rabbit. To analyse the binding by immunoﬂuorescence,
the cells were washed after incubation with the viral proteins, ﬁxed with 4%
paraformaldehyde (PFA) and subsequently stained using a monoclonal anti-SgG1
antibody (LP-10, kindly provided by Helena Browne, Cambridge University, UK),
an anti-SgG2 polyclonal antibody (Austral Biologicals), an anti-His tag antibody
(QIAGEN) to detect B18 and sema, and a polyclonal antibody to detect CXCR4
(Abcam) in the case of monocytes, which were incubated for 15min at 4 C or
37 C with 400 ng of SgG2 alone or in combination with CXCL12.
SPR assays for SgG-heparin binding and GAG competition. Kinetic studies
were perfomed injecting different concentrations of SgG2 over a streptavidin
sensor chip (BIAcore) with immobilized biotinylated heparin17. Bulk refractive
index changes were removed and curves were globally ﬁtted using a 1:1 mass
transport binding model. For competition assays, SgG2 (100 nM) was incubated
with different concentrations of soluble GAGs (Sigma), including heparin, heparan
sulfate, chondroitin sulfate A and chondroitin sulfate B for 10min. The mixture
was injected over a heparin-SA sensor chip at a 10 ml min 1 ﬂow rate, and the
response at equilibrium was recorded. All the assays were run in HBS-EP buffer
(10mM Hepes, 150mM NaCl, 3mM EDTA, 0.005% (vol/vol) surfactant P20,
pH 7.4).
Heparin–agarose-based pull-down assay. Different concentrations of SgG2 were
incubated for 1 h at RT with heparin–agarose beads (Sigma) in binding buffer
(0.2% bovine serum albumin (BSA) in phosphate-bufffered saline (PBS)). The
beads were washed three times with PBS and bound viral proteins were eluted with
SDS–polyacrylamide gel electrophoresis (SDS–PAGE) loading buffer, and then
subjected to SDS–PAGE and detected by immunoblotting.
ACP labelling reaction. CXCR4 was engineered with a tag at the amino (N)
terminus derived from the ACP and the labelling reaction was performed as
described22. Brieﬂy, the cells were washed with PBS containing calcium and
magnesium and incubated for 15min at RT with 5 mM CoA-Atto dye in the
presence of the enzyme (1 mM PPTase). The cells were washed to remove excess of
dye and immediately processed for time-lapse or immunoﬂuorescence. Since the
reagents used are non-cell permeable, this methodology enables the speciﬁc
labelling of surface CXCR4 (ref. 22).
Receptor internalization assays. The amount of surface CXCR4 was analysed by
ﬂow cytometry in MM-1 cells, Jurkat cells and primary monocytes. Cells were
mock treated or incubated with 1.5 mM SgG or PRV–SgG, 15 nM CXCL12 or the
complex vCKBP:CXCL12 at a 50:1 or 100:1 molar ratio for different time points.
After incubation at 37 C with the different stimuli, cells were kept at 4 C at all
times, and CXCR4 remaining at the surface was detected by ﬂow cytometry using a
PE-conjugated anti-CXCR4 antibody (R&D Systems). m300-19-hCXCR5 cells were
incubated with 15 nM CXCL13, 1.5 mM SgG2 or SgG2:CXCL13 at a 100:1 molar
ratio for 15min at 37 C. The cells were incubated with a PE-conjugated anti-
CXCR5 antibody (R&D Systems) at 4 C, and then surface receptor was analysed
by ﬂow cytometry. Similarly, for CCR2 analysis, MM-1 cells were incubated with
5 nM CCL2, 500 nM SgG2 or a combination of SgG2 and CCL2 at a 1:100 nM ratio
for 15min and the level of surface CCR2 was analysed by ﬂow cytometry using an
APC-conjugated anti-CCR2 antibody (R&D Systems). For CD71 internalization
studies, MM-1 cells were serum starved for 1 h before the assay, and then stimu-
lated with 1mgml 1 transferrin (Sigma), 1.5 mM SgG2 or both. The cells were
incubated with anti-CD71 (BD Pharmingen) and anti-mouse Alexa488-conjugated
antibody (Invitrogen) and receptor levels at the surface were analysed by ﬂow
cytometry. Data were collected on a FACSCalibur (Becton Dickinson) and analysed
using FlowJo 7.2.2 software (Treestar). The values obtained for each experimental
condition were represented as a percentage of the values corresponding to mock-
treated cells, which were assigned 100%. Typically, 105 cells were stained using 2 ml
of the indicated antibodies per reaction.
Analysis of CXCR4 incorporation into Lck10mCherry rafts. Jurkat cells
transduced with a lentiviral vector expressing the ﬂuorescent lipid raft marker
Lck10mCherry were stimulated for 30min with 8 nM CXCL12, 800 nM SgG2 or
PRV–SgG or the vCKBP:CXCL12 complex at a 100:1 molar ratio and then ﬁxed
with 4% ice-cold PFA. Subsequently, a polyclonal antibody (Abcam) was used
(10 mgml 1) to detect endogenous CXCR4.
Analysis of lipid raft clustering. Jurkat cells transduced with the ﬂuorescent lipid
raft marker Lck10mCherry were stained with Vybrant DiO plasma membrane
marker (Molecular Probes) following manufacturer’s instructions. Afterwards, the
cells were incubated for 30min at 37 C with 8 nM CXCL12, 800 nM SgG2 or
PRV–SgG or the vCBKPs:CXCL12 at a 100:1 molar ratio and subsequently ﬁxed
with 4% PFA. Pseudocoloured images showing Lck10mCherry clustering were
obtained using Image J software.
To investigate GM3 lipid raft clustering, Jurkat cells were stained using the
plasma membrane marker Vybrant DiD (Molecular Probes) and stimulated for
15min at 37 C using 8 nM CXCL12, 800 nM SgG1, SgG2 or PRV–SgG or the
vCKBP in combination with chemokine at a 100:1 molar ratio. The cells were ﬁxed
with 4% PFA and GM3 lipid rafts and CXCR4 were detected using a speciﬁc
antibody against GM3 (ref. 25) and a polyclonal antibody recognizing the receptor
(Abcam). A region of interest corresponding to the perimeter of the plasma
membrane was selected to generate the qualitative intensity histograms.
The area corresponding to GM1 and GM3 staining was analysed in primary
monocytes. The cells were stimulated with SgG1, SgG2, PRV–SgG, CXCL12 or the
vCKBPs:CXCL12 for 15min at 37 C, ﬁxed with PFA and stained to detect GM3
and GM1. The images were subjected to background correction and threshold
analysis to quantify the area corresponding to the different types of lipid raft
staining using Image J software.
CXCL12 immunoﬂuorescence and receptor phosphorylation. HEK-293T cells
expressing ACP-tagged CXCR4 were ACP-labelled and subsequently mock treated
or incubated with 8 nM CXCL12a-biotin/Qdots, 800 nM SgG2 or the complex
SgG2:CXCL12a-biotin/Qdots at a 100:1 molar ratio for 30min at 37 C. After-
wards, the cells were recorded for 30min at 37 C.
For the quantiﬁcation of CXCL12 and CXCR4 co-localization, ACP-CXCR4
HEK-293T cells were ACP-labelled and treated with 8 nM CXCL12-biotin/Qdots
alone or in the presence of 800 nM SgG2. The cells were ﬁxed with PFA after
30min of stimulation at 37 C and chemokine/receptor co-localization was
quantiﬁed using Image J software.
To analyse the localization of CXCL12, ACP-CXCR4 HEK-293T cells were
incubated during 45min at 37 C with 8 nM CXCL12-biotin/Qdots alone or in the
presence of 800 nM SgG2. Subsequently, the cells were washed with an acidic buffer
(glycine-HCl pH 3) for 30 s at 4 C following ﬁxation with PFA 4%. The area
corresponding to the CXCL12 ﬂuorescent signal was determined using Image J
software. Binding of CXCL12a-biotin/Qdots to lipid rafts was analysed in MDCK
cells stably expressing the Lck10mCherry marker. The cells were incubated with
8 nM CXCL12-biotin/Qdots, alone or in the presence of SgG2 (800 nM) for 30min
at 37 C, and then ﬁxed with 4% PFA. In both the experiments, images were
acquired using a Leica TCS SP5 confocal laser microscope.
For the analysis of CXCR4 and AP-2 co-localization, Flag-CXCR4-expressing
HEK-293T cells were stimulated with CXCL12, SgG2 or SgG2:CXCL12 for 5min at
37 C, and immediately ﬁxed and permeabilized with PBS containing 0,5% Triton
X-100. Afterwards, the cells were stained using antibodies directed against the Flag
tag (Sigma) and endogenous a-adaptin (BD Pharmingen). The images were
acquired using a Leica TCS SP5 confocal laser microscope.
Flag-CXCR4-expressing HEK-293T cells were serum starved and then
stimulated with 8 nM CXCL12, 800 nM SgG2 or SgG2:CXCL12 at a 100:1 molar
ratio (15–60min). After stimulation, the cells were lysed using 2 SDS-loading
buffer and then centrifuged at 20,000g for 15min. Samples were not boiled to
minimize receptor aggregation. Blots were incubated overnight in TBS-Tween
buffer containing 0.25% gelatin with the phospho-speciﬁc antibody anti-pSer330.
Membranes were stripped and probed with anti-tubulin as a loading control
(Sigma).
Isolation of lipid raft-enriched membrane fractions. Jurkat cells were stimulated
with 15 nM CXCL12, 1.5 mM SgG2, the complex SgG2:CXCL12 at a 100:1 molar
ratio or mock treated for 15min and then washed in HNEX buffer (25mM Hepes,
5mM EDTA, 150mM NaCl). A total of 50 107 cells were used per condition. The
cells were lysed in HNEX containing 0.5% Tritron X-100 and then overlaid with a
sucrose gradient (0.2–0.9M sucrose in HNEX). After centrifugation at 287,000g in
a SW41 rotor for 16 h, fractions were collected from top to bottom and proteins
were precipitated by adding TCA. The pellets were washed and solubilized in
Trizma buffer pH 9 (Sigma) by brief sonication in an ultrasound bath. Some of the
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fractions corresponding to lipid rafts were pooled, as indicated, and samples from
all the fractions were analysed by western blot using speciﬁc antibodies against
CXCR4 (Abcam) or LCK (kindly provided by M.A. Alonso, CBMSO, Spain).
GM1 was detected by dot blot using HRP-conjugated cholera toxin (20 mgml 1)
(Sigma).
Analysis of primary monocyte polarization. Freshly isolated monocytes were
adhered to coverslips coated with poly-D-lysine (Sigma) and the cells were mock
treated or stimulated with 8 nM CXCL12, 800 nM SgG1, SgG2 or PRV–SgG or with
the vCKBPs:CXCL12 complex at a 50:1 molar ratio for 5min at 37 C. After
stimulation, the cells were PFA-ﬁxed and stained using a polyclonal antibody
against CXCR4 (Abcam) and an anti-GM3 antibody25 or FITC-conjugated cholera
toxin b-subunit (5mgml 1) (Sigma) to detect GM3 and GM1 lipid rafts,
respectively.
Chemotaxis assays. Primary monocyte or MM-1 cell migration was analysed
using 96-well ChemoTx plates (Neuro Probe)5. Cells were incubated with the
chemical inhibitors for 30min at 37 C before the assay and the drugs were
maintained during the migration assay. The inhibitors were used at the following
concentrations: 7mM MbCD (Sigma), 50 mgml 1 ﬁlipin (Sigma), 1.5 mgml 1
nystatin (Sigma), 2 mM chlorpromazine (Sigma), 10 mM Src kinase inhibitor PP2
(Sigma) and 35mM PI3K inhibitor LY294002 (Calbiochem). The plates were
incubated at 37 C for 1 h (primary monocytes) or 2–3 h (MM-1 cells) and the
number of migrated cells was determined by staining the cells in the lower chamber
with 5 ml of CellTiter 96 aqueous one solution (Promega) in the case of MM-1 cells.
Primary monocytes were counted with a light microscope.
BRET assays. BRET assays were performed as previously described with minor
modiﬁcations26. Brieﬂy, HEK-293T cells were transfected with the donor construct
Rluc-CXCR4 (0.1 mg) and acceptor construct GFP2-CXCR4 (1mg) using Fugene
HD reagent (Promega) in 6-well plates and the total amount of DNA was adjusted
to 2 mg with empty vector. The cells were detached 24 h later and seeded at 5 105
cells per well in 96-well white plates (Corning) pretreated with poly-D-lysine and
poly-L-ornithine and cultured for an additional 24 h. The growing medium was
replaced with PBS containing 0.1% (w/v) glucose for 1 h before the assay. The cells
were treated with 1.5 mM SgG2, 15 nM CXCL12 or both at a 100:1 molar ratio
before the addition of freshly prepared DeepBlueC (DBC, 5 mM). BRET readings
were collected immediately after DBC addition, using a multidetector plate reader
(Tecan Inﬁnite F500). BRET signal was determined by calculating the ratio of the
light intensity emitted by the acceptor protein CXCR4-GFP2 (measured at
515±20 nm) over the light intensity emitted by the donor protein CXCR4-Rluc
(400±70 nm). The BRET ratio for each experimental condition was expressed over
the BRET ratio obtained for mock-treated cells. All the measurements were
corrected by subtracting the background BRET signal detected when Rluc-pcDNA
vector was expressed alone.
Immunogold labelling, replica preparation and electron microscopy analysis.
Immunogold-labelled cell surface replicas were obtained as described
previously27,28. In brief, Jurkat cells transiently expressing ACP-CXCR4 were
stimulated for 30min at 37 C with 15 nM CXCL12, 1.5 mM SgG2 or SgG2:CXCL12
at a 100:1 molar ratio, ﬁxed and labelled on ice with an anti-CXCR4 monoclonal
antibody (BD Pharmingen) or an isotype control antibody (BD Pharmingen).
Afterwards, cells were incubated with protein A conjugated to 10 nm gold particles
(Cell Microscopy Center), and attached to mica strips. For the preparation of cell
surface replicas by the label-fracture technique, samples were plunge frozen in
liquid propane, and then mounted on the sample table of a Balzers400T freeze
fracture (FF) unit under liquid nitrogen. The samples were placed in the FF unit,
cooled at  150 C and etched for 12min to remove excess of ice, and the stage
temperature was modiﬁed from  150 C to  90 C. The samples were shaded
with platinum (2 nm at 45 C angle) and coated with carbon (20 nm at 90 C
angle), removed from the FF unit and ﬂoated overnight on a domestic bleach
solution to remove the organic material. The replicas were extensively washed in
distilled water, mounted on 400 mesh copper grids and examined on a JEM1010
electron microscope (Jeol, Japan) operating at 80 kV. Images were taken at
 10,000 magniﬁcation (TemCam-F416 Camera). Overlapping photos of each cell
replica were merged with TVIPS software and gold particles were counted using
Cell Counter plugin from Image J software.
Video microscopy. HEK-293T cells were seeded on glass-bottom petri dishes
(MatTek cultureware) coated with poly-D-lysine (Sigma). Opti-MEM serum-free
medium (Gibco) was used during the assay. HEK-293T cell images shown in Fig. 2,
Fig. 5c and Supplementary Fig. 2, as well as movies shown in Supplementary
Movies 1 and 2 were obtained using a Leica DI6000 microscope stand connected to
a SP5 scan head equipped with a temperature-controlled chamber (Cube, LIS,
Basel). Images and videos were processed using Image J software.
Immunoﬂuorescence. For confocal microscopy, the cells were attached to poly-D-
lysine-treated coverslips. After stimulation with the chemokine, the vCKBPs or the
combination or both at the ratio indicated in each assay, the cells were PFA-ﬁxed
and incubated with PBS containing 2% FBS and 2% BSA. The incubation with the
primary or secondary Alexa-conjugated antibodies was routinely performed at
37 C for 1 h or 45min, respectively. The cells were incubated during 15min at RT
with DAPI reagent (Merck) or FITC-conjugated cholera toxin b (Sigma) when
needed. Coverslips were mounted with Prolong Gold antifade mounting medium
(Invitrogen). Images were taken by an AxioImager M2 microscopy system coupled
to a confocal LSM710 (Zeiss), using  63 and  100 PlanApochromat oil
immersion objective lens (1.4 numerical aperture) unless indicated. In all the cases,
images were obtained at a resolution of 1,024 1,024 pixels. The images were
subjected to background and mean ﬁlter correction using Image J 1.45 software.
All co-localization analyses were perfomed using the intensity correlation method
(ICA) detailed below.
Quantiﬁcation of co-localization. Pearson’s coefﬁcient (PC) is a standard sta-
tistical analysis designed to measure the strength of a linear relationship between
two variables; in this case, ﬂuorescent intensities from two images. PC generates a
range of values from 1, a perfect positive correlation, to  1, a perfect but inverse
correlation, with 0 representing a random distribution. To perform a more detailed
analysis, we took advantage of a recently developed correlation method termed
ICA57. The ICA method is based on the principle that if two proteins are part of
the same complex then their staining intensities should vary in synchrony, whereas
if they form a part of different complexes or structures they will exhibit
asynchronous staining. ICA analysis involves generating scatter-plots of stain A or
stain B against the product of the difference of each pixel A and B intensities from
their respective means. The resulting plots emphasize the high-intensity stained
pixels and allow us to identify protein pairs that vary in synchrony, randomly or
independently within the cell. The intensity correlation quotient was used to
provide an overall index of whether the staining intensities are associated in a
random, a dependent or a segregated manner. The outlining of regions in which
two probes may distribute is essential to obtain accurate measurements of
co-localization58. Therefore regions of interest were drawn when necessary.
A minimum of three different sections were quantiﬁed in the assays shown.
Statistical analysis. The signiﬁcant value (P value) was calculated using
GraphPad Prism.
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